热门资讯> 正文
世卫组织推荐吉利德每年两次的艾滋病毒预防药物Yeztugo
2025-07-14 23:22
- 希伦布兰德(HI) 0
- WSP控股(WH) 0
- 吉利德科学(GILD) 0
- The World Health Organization has recommended Gilead Sciences' (NASDAQ:GILD) recently FDA-approved twice yearly HIV pre-exposure prophylaxis (PrEP) treatment Yeztugo (lenacapavir).
- "With just two doses per year, [Yeztugo] is a transformative step forward in protecting people at risk of HIV – particularly those who face challenges with daily adherence, stigma, or access to health care," the organization said in a press release.
- While WHO noted that access to Yeztugo is currently limited, it is urging "governments, donors and global health partners to begin rolling out [lenacapavir] immediately within national combination HIV prevention programmes – while collecting essential data on uptake, adherence and real-world impact."
More on Gilead Sciences
- Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats
- Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
- Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
- Gilead sees Q2 EPS hit from IPR&D expenses
- Arcus says Gilead-partnered cancer drug won FDA orphan status
推荐文章
美股机会日报丨关税大消息！涉及欧盟、日本；科技巨头财报夜：谷歌、特斯拉能否搅动市场情绪？
特朗普即将揭晓“AI行动计划”，这些美股有望赢政策利好，谁将从中“分羹”？
美股异动丨英伟达、博通跌超3%，稳定币巨头Circle跌超7%
美股机会日报丨鲍威尔发言在即！散户疯炒，“Meme股”OPEN盘前涨超23%
特朗普媒体公司囤积20亿美元比特币！加密货币推动特朗普净资产大幅增长
AI和机器人有望刺激特斯拉股价？财报季提前部署期权策略
华盛早报丨科技“七巨头“财报来袭定调美股走向！金融科技公司Block获入标普500指数
美股“七巨头”迎特朗普关税后首次大考！Q2能否交出亮眼成绩单，继续引领美股上涨？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
